Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Foslinanib,Sorafenib
Therapeutic Area : Oncology
Study Phase : Phase II
Recipient : Bora Pharmaceuticals
Deal Size : Undisclosed
Deal Type : Partnership
Bora Pharmaceuticals Partners with TaiRx
Details : CVM-1118 (foslinanib) is a new small molecule chemical entity and a potential anti-cancer agent in numerous human cancer cell lines with strong anti-cancer activity, high safety margin, and multiple mechanisms of actions in targeting cancer-specific fact...
Brand Name : CVM-1118
Molecule Type : Small molecule
Upfront Cash : Undisclosed
September 27, 2022
Lead Product(s) : Foslinanib,Sorafenib
Therapeutic Area : Oncology
Highest Development Status : Phase II
Recipient : Bora Pharmaceuticals
Deal Size : Undisclosed
Deal Type : Partnership
LOOKING FOR A SUPPLIER?